Skip to main content
PMC home page
Journal of Clinical Pathology logoLink to Journal of Clinical Pathology
. 1994 Jul;47(7):619–624. doi: 10.1136/jcp.47.7.619

Specificity and sensitivity of immunocytochemistry for detecting P-glycoprotein in haematological malignancies.

J L Gala 1, J M McLachlan 1, D R Bell 1, J L Michaux 1, D D Ma 1
PMCID: PMC502088  PMID: 7916349

Abstract

AIMS--To determine the optimal working conditions of the alkaline phosphatase-antialkaline phosphatase (APAAP) method to establish a specific and sensitive assay for the detection of low numbers of MDR positive cells in patients with hematological malignancies. METHODS--Three monoclonal antibodies (C-219, JSB-1, MRK-16) were used for the detection of P-glycoprotein (P-gp) in cell lines and in samples from 43 patients with haematological malignancies. The results of the APAAP method were compared with western blotting for specificity and sensitivity. RESULTS--Excellent correlation was obtained between optimised APAAP and western blotting, except in the case of multiple myeloma. JSB-1 seemed to be the more useful monoclonal antibody for the APAAP which was more sensitive than western blotting in its ability to detect single P-gp positive cells. CONCLUSIONS--Methods for P-gp detection, as defined by multidrug resistant (MDR) cell lines, are not necessarily optimal and specific for clinical samples and may lead to higher false positive and negative results, according to the conditions and the monoclonal antibodies used.

Full text

PDF
619

Images in this article

621Image
on p.621
623Image
on p.623

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bell D. R., Gerlach J. H., Kartner N., Buick R. N., Ling V. Detection of P-glycoprotein in ovarian cancer: a molecular marker associated with multidrug resistance. J Clin Oncol. 1985 Mar;3(3):311–315. doi: 10.1200/JCO.1985.3.3.311. [DOI] [PubMed] [Google Scholar]
  2. Chan H. S., Haddad G., Thorner P. S., DeBoer G., Lin Y. P., Ondrusek N., Yeger H., Ling V. P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma. N Engl J Med. 1991 Dec 5;325(23):1608–1614. doi: 10.1056/NEJM199112053252304. [DOI] [PubMed] [Google Scholar]
  3. Cordell J. L., Falini B., Erber W. N., Ghosh A. K., Abdulaziz Z., MacDonald S., Pulford K. A., Stein H., Mason D. Y. Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). J Histochem Cytochem. 1984 Feb;32(2):219–229. doi: 10.1177/32.2.6198355. [DOI] [PubMed] [Google Scholar]
  4. Cumber P. M., Jacobs A., Hoy T., Fisher J., Whittaker J. A., Tsuruo T., Padua R. A. Expression of the multiple drug resistance gene (mdr-1) and epitope masking in chronic lymphatic leukaemia. Br J Haematol. 1990 Oct;76(2):226–230. doi: 10.1111/j.1365-2141.1990.tb07876.x. [DOI] [PubMed] [Google Scholar]
  5. Dalton W. S., Grogan T. M., Meltzer P. S., Scheper R. J., Durie B. G., Taylor C. W., Miller T. P., Salmon S. E. Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. J Clin Oncol. 1989 Apr;7(4):415–424. doi: 10.1200/JCO.1989.7.4.415. [DOI] [PubMed] [Google Scholar]
  6. Dalton W. S., Grogan T. M., Rybski J. A., Scheper R. J., Richter L., Kailey J., Broxterman H. J., Pinedo H. M., Salmon S. E. Immunohistochemical detection and quantitation of P-glycoprotein in multiple drug-resistant human myeloma cells: association with level of drug resistance and drug accumulation. Blood. 1989 Feb 15;73(3):747–752. [PubMed] [Google Scholar]
  7. Danks M. K., Metzger D. W., Ashmun R. A., Beck W. T. Monoclonal antibodies to glycoproteins of Vinca alkaloid-resistant human leukemic cells. Cancer Res. 1985 Jul;45(7):3220–3224. [PubMed] [Google Scholar]
  8. Epstein J., Xiao H. Q., Oba B. K. P-glycoprotein expression in plasma-cell myeloma is associated with resistance to VAD. Blood. 1989 Aug 15;74(3):913–917. [PubMed] [Google Scholar]
  9. Erber W. N., Mynheer L. C., Mason D. Y. APAAP labelling of blood and bone-marrow samples for phenotyping leukaemia. Lancet. 1986 Apr 5;1(8484):761–765. doi: 10.1016/s0140-6736(86)91781-2. [DOI] [PubMed] [Google Scholar]
  10. Fojo A., Akiyama S., Gottesman M. M., Pastan I. Reduced drug accumulation in multiply drug-resistant human KB carcinoma cell lines. Cancer Res. 1985 Jul;45(7):3002–3007. [PubMed] [Google Scholar]
  11. Georges E., Bradley G., Gariepy J., Ling V. Detection of P-glycoprotein isoforms by gene-specific monoclonal antibodies. Proc Natl Acad Sci U S A. 1990 Jan;87(1):152–156. doi: 10.1073/pnas.87.1.152. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Gerlach J. H., Kartner N., Bell D. R., Ling V. Multidrug resistance. Cancer Surv. 1986;5(1):25–46. [PubMed] [Google Scholar]
  13. Goldstein L. J., Galski H., Fojo A., Willingham M., Lai S. L., Gazdar A., Pirker R., Green A., Crist W., Brodeur G. M. Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst. 1989 Jan 18;81(2):116–124. doi: 10.1093/jnci/81.2.116. [DOI] [PubMed] [Google Scholar]
  14. Gottesman M. M., Pastan I. The multidrug transporter, a double-edged sword. J Biol Chem. 1988 Sep 5;263(25):12163–12166. [PubMed] [Google Scholar]
  15. Grogan T., Dalton W., Rybski J., Spier C., Meltzer P., Richter L., Gleason M., Pindur J., Cline A., Scheper R. Optimization of immunocytochemical P-glycoprotein assessment in multidrug-resistant plasma cell myeloma using three antibodies. Lab Invest. 1990 Dec;63(6):815–824. [PubMed] [Google Scholar]
  16. Hamada H., Tsuruo T. Functional role for the 170- to 180-kDa glycoprotein specific to drug-resistant tumor cells as revealed by monoclonal antibodies. Proc Natl Acad Sci U S A. 1986 Oct;83(20):7785–7789. doi: 10.1073/pnas.83.20.7785. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Hitchins R. N., Harman D. H., Davey R. A., Bell D. R. Identification of a multidrug resistance associated antigen (P-glycoprotein) in normal human tissues. Eur J Cancer Clin Oncol. 1988 Mar;24(3):449–454. doi: 10.1016/s0277-5379(98)90015-3. [DOI] [PubMed] [Google Scholar]
  18. Holmes J., Jacobs A., Carter G., Janowska-Wieczorek A., Padua R. A. Multidrug resistance in haemopoietic cell lines, myelodysplastic syndromes and acute myeloblastic leukaemia. Br J Haematol. 1989 May;72(1):40–44. doi: 10.1111/j.1365-2141.1989.tb07649.x. [DOI] [PubMed] [Google Scholar]
  19. Kartner N., Evernden-Porelle D., Bradley G., Ling V. Detection of P-glycoprotein in multidrug-resistant cell lines by monoclonal antibodies. 1985 Aug 29-Sep 4Nature. 316(6031):820–823. doi: 10.1038/316820a0. [DOI] [PubMed] [Google Scholar]
  20. Kartner N., Riordan J. R., Ling V. Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines. Science. 1983 Sep 23;221(4617):1285–1288. doi: 10.1126/science.6137059. [DOI] [PubMed] [Google Scholar]
  21. Kuwazuru Y., Hanada S., Furukawa T., Yoshimura A., Sumizawa T., Utsunomiya A., Ishibashi K., Saito T., Uozumi K., Maruyama M. Expression of P-glycoprotein in adult T-cell leukemia cells. Blood. 1990 Nov 15;76(10):2065–2071. [PubMed] [Google Scholar]
  22. Ling V., Thompson L. H. Reduced permeability in CHO cells as a mechanism of resistance to colchicine. J Cell Physiol. 1974 Feb;83(1):103–116. doi: 10.1002/jcp.1040830114. [DOI] [PubMed] [Google Scholar]
  23. Ma D. D., Bell D. R. Multidrug resistance and P-glycoprotein expression in human cancer. Aust N Z J Med. 1989 Dec;19(6):736–743. doi: 10.1111/j.1445-5994.1989.tb00351.x. [DOI] [PubMed] [Google Scholar]
  24. Marie J. P., Zittoun R., Sikic B. I. Multidrug resistance (mdr1) gene expression in adult acute leukemias: correlations with treatment outcome and in vitro drug sensitivity. Blood. 1991 Aug 1;78(3):586–592. [PubMed] [Google Scholar]
  25. Miller T. P., Grogan T. M., Dalton W. S., Spier C. M., Scheper R. J., Salmon S. E. P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil. J Clin Oncol. 1991 Jan;9(1):17–24. doi: 10.1200/JCO.1991.9.1.17. [DOI] [PubMed] [Google Scholar]
  26. Musto P., Melillo L., Lombardi G., Matera R., di Giorgio G., Carotenuto M. High risk of early resistant relapse for leukaemic patients with presence of multidrug resistance associated P-glycoprotein positive cells in complete remission. Br J Haematol. 1991 Jan;77(1):50–53. doi: 10.1111/j.1365-2141.1991.tb07947.x. [DOI] [PubMed] [Google Scholar]
  27. Pastan I., Gottesman M. Multiple-drug resistance in human cancer. N Engl J Med. 1987 May 28;316(22):1388–1393. doi: 10.1056/NEJM198705283162207. [DOI] [PubMed] [Google Scholar]
  28. Riordan J. R., Ling V. Genetic and biochemical characterization of multidrug resistance. Pharmacol Ther. 1985;28(1):51–75. doi: 10.1016/0163-7258(85)90082-8. [DOI] [PubMed] [Google Scholar]
  29. Salmon S. E., Dalton W. S., Grogan T. M., Plezia P., Lehnert M., Roe D. J., Miller T. P. Multidrug-resistant myeloma: laboratory and clinical effects of verapamil as a chemosensitizer. Blood. 1991 Jul 1;78(1):44–50. [PubMed] [Google Scholar]
  30. Sato H., Preisler H., Day R., Raza A., Larson R., Browman G., Goldberg J., Vogler R., Grunwald H., Gottlieb A. MDR1 transcript levels as an indication of resistant disease in acute myelogenous leukaemia. Br J Haematol. 1990 Jul;75(3):340–345. doi: 10.1111/j.1365-2141.1990.tb04346.x. [DOI] [PubMed] [Google Scholar]
  31. Scheper R. J., Bulte J. W., Brakkee J. G., Quak J. J., van der Schoot E., Balm A. J., Meijer C. J., Broxterman H. J., Kuiper C. M., Lankelma J. Monoclonal antibody JSB-1 detects a highly conserved epitope on the P-glycoprotein associated with multi-drug-resistance. Int J Cancer. 1988 Sep 15;42(3):389–394. doi: 10.1002/ijc.2910420314. [DOI] [PubMed] [Google Scholar]
  32. Shustik C., Groulx N., Gros P. Analysis of multidrug resistance (MDR-1) gene expression in chronic lymphocytic leukaemia (CLL). Br J Haematol. 1991 Sep;79(1):50–56. doi: 10.1111/j.1365-2141.1991.tb08006.x. [DOI] [PubMed] [Google Scholar]
  33. Skovsgaard T. Mechanism of cross-resistance between vincristine and daunorubicin in Ehrlich ascites tumor cells. Cancer Res. 1978 Dec;38(12):4722–4727. [PubMed] [Google Scholar]
  34. Volm M., Efferth T., Bak M., Ho A. D., Mattern J. Detection of the multidrug resistant phenotype in human tumours by monoclonal antibodies and the streptavidin-biotinylated phycoerythrin complex method. Eur J Cancer Clin Oncol. 1989 Apr;25(4):743–749. doi: 10.1016/0277-5379(89)90213-7. [DOI] [PubMed] [Google Scholar]
  35. Weide R., Dowding C., Paulsen W., Goldman J. The role of the MDR-1/P-170 mechanism in the development of multidrug resistance in chronic myeloid leukemia. Leukemia. 1990 Oct;4(10):695–699. [PubMed] [Google Scholar]
  36. van der Valk P., van Kalken C. K., Ketelaars H., Broxterman H. J., Scheffer G., Kuiper C. M., Tsuruo T., Lankelma J., Meijer C. J., Pinedo H. M. Distribution of multi-drug resistance-associated P-glycoprotein in normal and neoplastic human tissues. Analysis with 3 monoclonal antibodies recognizing different epitopes of the P-glycoprotein molecule. Ann Oncol. 1990;1(1):56–64. [PubMed] [Google Scholar]

Articles from Journal of Clinical Pathology are provided here courtesy of BMJ Publishing Group

RESOURCES